- |||||||||| rivaroxaban / Generic mfg.
Clinical, Journal, HEOR, Real-world evidence: Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban. (Pubmed Central) - Sep 20, 2019
In addition to advice for appraising data quality and study designs, several updates will be covered from real-world studies of rivaroxaban for stroke prevention in patients with atrial fibrillation (AF): the nationwide Danish cohort study, U.S. Department of Defense Military Health System database, retrospective claim database study REAFFIRM and a pooled analysis from the global NIS XArelto on preveNtion of sTroke and non-central nervoUS system systemic embolism in patients with non-valvular atrial fibrillation (XANTUS). Real-world studies consistently show that rivaroxaban is an effective treatment option with acceptable safety when used for stroke prevention in a large number of patients with AF across the globe.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J
Journal: The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease. (Pubmed Central) - Sep 20, 2019
An increased understanding of the interactions taking place within the coagulation cascade may support a broader role for rivaroxaban (2.5 mg twice daily [bid] or 5 mg bid) in the setting of vascular protection, either alone or in combination with an antiplatelet agent. The aim of this article is to describe the potential role of rivaroxaban in the context of vascular protection and provide an overview of recently completed and ongoing randomized controlled trials of rivaroxaban in the areas of stroke prevention, venous protection and vascular protection.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J
Journal: Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban. (Pubmed Central) - Sep 20, 2019
This article provides an update on three randomized controlled trials of rivaroxaban, a direct, oral factor Xa inhibitor, that are complete or are ongoing, in these unmet areas of stroke prevention: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention (PIONEER AF-PCI) trial; the New Approach riVaroxaban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS) trial and the Global study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement to Optimize clinical outcomes (GALILEO) trial. The data from these studies are anticipated to help address continuing challenges for a range of patients at risk of stroke.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J
Journal: Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. (Pubmed Central) - Sep 20, 2019
Here, we present overviews of three CALLISTO studies: PRO-LAPS II, CASTA-DIVA and COSIMO. Currently available and anticipated results from studies in a variety of patients at risk of or with VTE will provide valuable insights and seek to optimize future VTE management.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J, warfarin / Generic Mfg.
Clinical, Journal: Use of oral anticoagulants in complex clinical situations with atrial fibrillation. (Pubmed Central) - Sep 20, 2019
In mild and moderate stages, direct-acting anticoagulants confer a greater benefit than warfarin, although they usually require dose adjustment...In the context of their use before and after atrial fibrillation ablation, dabiga-tran and rivaroxaban have demonstrated at least non-inferiority with vitamin K antagonists in terms of safety...Moreover, any such decision should be consensus-based and periodically reviewed. Direct-acting anticoa-gulants could be the most beneficial alternative in most elderly patients with non-valvular atrial fibrillation.
- |||||||||| Journal: When to stop anticoagulation, anti-platelet aggregates, and non-steroidal anti-inflammatories (NSAIDs) prior to spine surgery. (Pubmed Central) - Sep 19, 2019
The anti-platelet aggregates include: Aspirin/Clopidogrel (stop >7-10 days preoperatively)...NSAIDs (generic name/commercial names should be stopped preoperatively for at least; 1 day- Diclofenac (Voltaran), Ibuprofen (Advil, Motrin), Ketorolac (Toradol); 2 days- Etodolac (Lodine), Indomethacin (Indocin); 4-days-Meloxicam (Mobic) and Naproxen (Aleve, Naprosyn, Anaprox); 4 days- Nabumetone (Relafen); 6 days - Oxaprozin (Daypro); and 10 days- Piroxicam (Feldene). Spine surgeons need to know when anti-platelet, anticoagulant, and NSAIDs therapies should be stopped prior to spine surgery to avoid perioperative bleeding complications.
- |||||||||| Retrospective data: Association of Novel Oral Antithrombotics With the Risk of Intraocular Bleeding. (Pubmed Central) - Sep 18, 2019
A total of 103 796 patients taking clopidogrel (37 578 women and 66 218 men; mean [SD] age, 68.0 [11.3] years) were compared with 8386 patients taking prasugrel (1988 women and 6380 men; mean [SD] age, 61.0 [9.6] years) and no increased hazard for developing an intraocular hemorrhage with prasugrel was seen at 90 days (HR, 0.75; 95% CI, 0.29-1.92; P = .55) or 365 days (HR, 1.19; 95% CI, 0.69-2.04; P = .53). These results suggest a decreased risk of intraocular hemorrhage associated with novel direct thrombin inhibitors and direct factor Xa inhibitors, but no difference for P2Y12 inhibitors compared with traditional vitamin K anticoagulation and antiplatelet therapy, respectively.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J, warfarin / Generic Mfg.
Review, Journal: Use of direct oral anticoagulants in antiphospholipid syndrome. (Pubmed Central) - Sep 18, 2019
Ongoing and emerging DOAC RCTs should provide further information to guide the use of DOACs in APS. Optimal identification of APS patients is a key step in working towards improved therapeutic strategies in these individuals.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg., Eliquis (apixaban) / BMS
Retrospective data, Review, Journal: Reduced dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. (Pubmed Central) - Sep 18, 2019
Efficacy benefits were, in part, offset by bleeding outcomes. Extended duration treatment of VTE with reduced dose DOAC may be as efficacious as full dose treatment, with rates of major bleeding similar to treatment with aspirin or placebo, but further long-term studies are needed.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J, warfarin / Generic Mfg.
Journal: Warfarin-resistant left ventricular thrombus completely dissolved by rivaroxaban. (Pubmed Central) - Sep 18, 2019
The analytical performance of plasma rivaroxaban was acceptable in both systems, and results from reagent/coagulometer systems are comparable even when calibrating with different branch material. No abstract available
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
Clinical, Journal: Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. (Pubmed Central) - Sep 18, 2019
P=N/A
Due to the complexity of DOAC management, potentially-inappropriate prescribing and drug related problems are common. Multidisciplinary collaborative projects including review and consultation by clinical pharmacists are an effective method of improving management of patients on DOAC.
- |||||||||| AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
Review, Journal: A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet alfa (Andexxa®). (Pubmed Central) - Sep 16, 2019
This accelerated approval was based on change in anti FXa activity from baseline, which indicates a reversal of the anticoagulant effect. Any expanded FDA indication will be contingent on results demonstrating improved hemostasis and efficacy for reversibility of other FXa inhibitors.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, warfarin / Generic Mfg.
Clinical, Journal: Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan. (Pubmed Central) - Sep 14, 2019
Individuals with AF aged 85 and older who used reduced-dose dabigatran or reduced-dose rivaroxaban had statistically significantly lower all-cause mortality and cardiovascular mortality than those who used warfarin. Reduced-dose dabigatran was also associated with lower risk of intracranial hemorrhage than warfarin.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg.
Clinical, Journal: Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. (Pubmed Central) - Sep 14, 2019
New perspectives for anti-thrombotic therapy for the treatment of patients with CAAD come from the novel dual pathway strategy combining a low-dose anticoagulant (i.e. rivaroxaban) and aspirin that may help reduce long-term ischaemic complications in patients with CAAD. This review summarizes current evidence and recommendations for the anti-thrombotic management of patients with symptomatic or asymptomatic CAAD or those undergoing carotid revascularization.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J
Journal, Monotherapy: Rivaroxaban monotherapy for AF and stable CAD. (Pubmed Central) - Sep 13, 2019
Our results may provide useful information for treatment with oral anticoagulants, although further studies with more data are needed. No abstract available
- |||||||||| rivaroxaban / Generic mfg., lenalidomide / Generic mfg., aspirin / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy: RithMM: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (clinicaltrials.gov) - Sep 13, 2019
P2/3, N=86, Recruiting,
No abstract available Not yet recruiting --> Recruiting | Trial completion date: Jan 2019 --> Jan 2021 | Trial primary completion date: Nov 2018 --> Jan 2020
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
Clinical, Journal: Clinical impact of direct oral anticoagulant measuring in a real-life setting. (Pubmed Central) - Sep 12, 2019
DOAC testing had a significant impact on clinical management in the majority of patients. The study highlights the importance of availability to specific DOAC tests, especially in institutions handling emergent settings.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J
Journal: Stroke prevention: Learning from the master (and COMMANDER). (Pubmed Central) - Sep 12, 2019
The study highlights the importance of availability to specific DOAC tests, especially in institutions handling emergent settings. Adding rivaroxaban to standard therapy in patients with heart failure and no atrial fibrillation did not show any beneficial effect on death risk.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J
Clinical, Journal: Is the Oral Chemical Prophylaxis Necessary for the Prevention of Venous Thromboembolism after Joint Arthroplasty in a Korean Population? (Pubmed Central) - Sep 11, 2019
...The aim of the present study was to determine the necessity of a chemical thromboprophylactic agent (rivaroxaban [RXB]) by analyzing the prevalence of VTE in Korean arthroplasty patients who received RXB for prophylaxis compared with those who did not receive RXB...Furthermore, no serious complications occurred after administering oral RXB, which, coupled with its convenience, suggests oral RXB offers an attractive alternative to other agents. However, we recommend that further studies, including a multicenter study, be conducted to achieve adequate statistical power.
- |||||||||| Journal: Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence. (Pubmed Central) - Sep 11, 2019
DOACs may be an attractive alternative to warfarin because of fast onset of action, potentially reducing delay to cardioversion. More robust studies are needed in patients with renal dysfunction and patients undergoing pharmacological cardioversion.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J, Eliquis (apixaban) / BMS
Journal: Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban. (Pubmed Central) - Sep 11, 2019
Good correlation was shown between anti-Xa activity and serum levels. The clinical utility of monitoring anti-Xa activity and the significance of the difference in trough anti-Xa activity for these agents remains to be established.
- |||||||||| Xarelto (rivaroxaban) / J&J
Trial completion date, Trial primary completion date, Adverse events: Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden) (clinicaltrials.gov) - Sep 11, 2019
P=N/A, N=40000, Recruiting,
This study demonstrates the capability of Sentinel to conduct prospective safety monitoring and raises no new concerns about rivaroxaban safety. Trial completion date: Aug 2020 --> Apr 2020 | Trial primary completion date: Aug 2020 --> Oct 2019
- |||||||||| Clinical, Review, Journal: Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists. (Pubmed Central) - Sep 10, 2019
DOACs are associated with lower rates of major and fatal bleeding events compared with warfarin...Idarucizumab and andexanet alfa, which reverse the anticoagulant effects of dabigatran and FXa inhibitors, respectively, are DOAC reversal agents available in the US...However, specific reversal agents are efficacious and safe and should be preferred when available. In this review, we discuss practical issues in the initiation of DOAC therapy, situations where reversal may be needed, coagulation assays, reversal agents, and post-reversal complications in the context of published evidence and guidelines.
- |||||||||| Rituxan (rituximab) / Roche, Biogen
RELAPSING MARANTIC ENDOCARDITIS IN APS - SLE - TROMBOPHILIC PATIENT. () - Sep 10, 2019 - Abstract #EUSEM2019EUSEM_1499;
Discussion This case is interesting because of the exuberance, recurrence and refractoriness of this ME that may be explained on the basis of the multifactorial etiology of her hypercoagulable state. Studies are needed to evaluate the benefit of immunosuppressant therapy in refractory and recurrent ME as well as the role of different anticoagulant therapies.
- |||||||||| Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg.
A rare case of intra abdominal bleeding:spontaneous rupture of superior mesenteric artery pseudoaneurysm. () - Sep 10, 2019 - Abstract #EUSEM2019EUSEM_1237;
Multidisciplinary approach is required, starting from treatment of shock (including inotropes) with activation of massive haemorrhage protocol and definitive haemorrhage control (angioembolization) achieved in theatre environment. Disclaimer Patient consented to use of details and imaging for purpose of this abstract.
|
